Cho MS, et al. - Using nationwide administrative claims-based datasets from the Korean National Health Insurance Service Database (July 1, 2015, to December 31, 2016), researchers compared the efficacy and safety outcomes of standard- and low-dose non–vitamin K antagonist oral anticoagulants (NOACs) and warfarin in 56,504 East Asian patients with nonvalvular atrial fibrillation. Findings suggested an association of NOACs with better effectiveness and safety outcomes compared to warfarin. Use of low-dose apixaban did not show clinical benefit over warfarin with respect to thromboembolic events (ischemic stroke or systemic embolism) and mortality among adults <75 years of age without chronic kidney disease. They found that lower NOAC doses were used more often, but an unjustified underdosage of apixaban appears to lead to a lower clinical benefit.